The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Compare the epidemiologic and reproductive risk factors in BOTs with those in ovarian cancers and describe the molecular background of development of BOTs.Use the pathological terminology with either original grouping of borderline category or new subclassification of BOTs and assess the major predictor of recurrence and survival.Determine an appropriate diagnostic algorithm for patients with symptoms suggesting malignant ovarian tumors that will identify borderline ovarian tumors when present. CME This article is available for continuing medical education credit at CME.TheOncologist.com Borderline ovarian tumors represent a heterogeneous group of noninvasive tumors of uncertain malignant potential with characteristic histology. They occur in younger women, are present at an early stage, and have a favorable prognosis, but symptomatic recurrence and death may be found as long as 20 years after therapy in some patients. The molecular changes in borderline ovarian tumors indicate linkage of this disease to type I ovarian tumors (low-grade ovarian carcinomas). The pathological stage of disease and subclassification of extraovarian disease into invasive and noninvasive implants, together with the presence of postoperative macroscopic residual disease, appear to be the major predictor of recurrence and survival. However, it should be emphasized that the most important negative prognostic factor for recurrence is just the use of conservative surgery, but without any impact on patient survival because most recurrent diseases are of the borderline type—easily curable and with an excellent prognosis. Borderline tumors are difficult masses to correctly preoperatively diagnose using imaging methods because their macroscopic features may overlap with invasive and benign ovarian tumors. Over the past several decades, surgical therapy has shifted from a radical approach to more conservative treatment; however, oncologic safety must always be balanced. Follow-up is essential using routine ultrasound imaging, with special attention paid to the remaining ovary in conservatively treated patients. Current literature on this topic leads to a number of controversies that will be discussed thoroughly in this article, with the aim to provide recommendations for the clinical management of these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Pathology and Genetics of Tumours of the Breast and Female Genital Organs
Tavassoli, F. A., & Devilee, P. (2003) · International Agency for Research on Cancer eBooks · Cited by 2,800
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
Blaustein's Pathology of the Female Genital Tract
(2019) · Springer eBooks · doi:10.1007/978-3-319-46334-6 · Cited by 1,335
HEINTZ, A., ODICINO, F., MAISONNEUVE, P., QUINN, M., BENEDET, J., CREASMAN, W., NGAN, H., PECORELLI, S., & BELLER, U. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60033-7 · Cited by 1,277
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Epigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143
INCESSANT OVULATION—A FACTOR IN OVARIAN NEOPLASIA ?
Fathalla, M. F. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92335-x · Cited by 1,119
Benedet, J. L. (2000) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(00)00300-3 · Cited by 1,104
JACOBS, I., ORAM, D., FAIRBANKS, J., TURNER, J., FROST, C., & GRUDZINSKAS, J. G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb02448.x · Cited by 962
(2000) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(00)90001-8 · Cited by 891
Walker, R. A. (2005) · Histopathology · doi:10.1111/j.1365-2559.2004.02026.x · Cited by 839
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) · The Lancet · doi:10.1016/s0140-6736(08)60167-1 · Cited by 822
Blaustein’s Pathology of the Female Genital Tract
(2011) · Springer eBooks · doi:10.1007/978-1-4419-0489-8 · Cited by 668
Preservation of Fertility in Patients with Cancer
Jeruss, J. S., & Woodruff, T. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801454 · Cited by 583
Whittemore, A. S., Harris, R., Itnyre, J., Halpern, J., & the Collaborative Ovarian Cancer Group (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116426 · Cited by 525
Timmerman, D., Ameye, L., Fischerova, D., Epstein, E., Melis, G. B., Guerriero, S., Van Holsbeke, C., Savelli, L., Fruscio, R., Lissoni, A. A., et al. (2010) · BMJ · doi:10.1136/bmj.c6839 · Cited by 478
Self-citationInfertility, Fertility Drugs, and Ovarian Cancer: A Pooled Analysis of Case-Control Studies
Ness, R. B. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.3.217 · Cited by 422
Zanetta, G., Rota, S., Chiari, S., Bonazzi, C., Bratina, G., & Mangioni, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2658 · Cited by 420
Seidman, J. D., & Kurman, R. J. (2000) · Human Pathology · doi:10.1053/hp.2000.8048 · Cited by 410
Origins and molecular pathology of ovarian cancer
Bell, D. A. (2005) · Modern Pathology · doi:10.1016/s0893-3952(22)04456-8 · Cited by 387
Timmerman, D., Schwärzler, P., Collins, W. P., Claerhout, F., Coenen, M., Amant, F., Vergote, I., & Bourne, T. H. (1999) · Ultrasound in Obstetrics & Gynecology · doi:10.1046/j.1469-0705.1999.13010011.x · Cited by 300
Endometriomas: their ultrasound characteristics
Van Holsbeke, C., Van Calster, B., Guerriero, S., Savelli, L., Paladini, D., Lissoni, A. A., Czekierdowski, A., Fischerova, D., Zhang, J., Mestdagh, G., et al. (2010) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.7668 · Cited by 299
Self-citationClinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Seidman, J. D., & Kurman, R. J. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199611000-00004 · Cited by 290
Serous Borderline Tumors of the Ovary
Prat, J., & Nictolis, M. D. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200209000-00002 · Cited by 283
Harris, R., Whittemore, A. S., & Itnyre, J. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116428 · Cited by 275
Skírnisdóttir, I., Garmo, H., Wilander, E., & Holmberg, L. (2008) · International Journal of Cancer · doi:10.1002/ijc.23724 · Cited by 246
Hormonal contraception and risk of cancer
Cibula, D., Gompel, A., Mueck, A. O., La Vecchia, C., Hannaford, P. C., Skouby, S. O., Zikan, M., & Dusek, L. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq022 · Cited by 246
Self-citationValentin, L., Hagen, B., Tingulstad, S., & Eik‐Nes, S. (2001) · Ultrasound in Obstetrics & Gynecology · doi:10.1046/j.0960-7692.2001.00500.x · Cited by 227
Ovarian serous borderline tumors with invasive peritoneal implants
Gershenson, D. M., Silva, E. G., Levy, L., Burke, T. W., Wolf, J. K., & Tornos, C. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980315)82:6<1096::aid-cncr13>3.0.co;2-1 · Cited by 203
Use of morphology to characterize and manage common adnexal masses
Valentin, L. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2003.10.002 · Cited by 194
Sokalska, A., Timmerman, D., Testa, A. C., Van Holsbeke, C., Lissoni, A. A., Leone, F. P. G., Jurkovic, D., & Valentin, L. (2009) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.6444 · Cited by 194
Silva, E. G., Gershenson, D. M., Malpica, A., & Deavers, M. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213294.81154.95 · Cited by 192
van Leeuwen, F. E., Klip, H., Mooij, T. M., van de Swaluw, A. M. G., Lambalk, C. B., Kortman, M., Laven, J. S. E., Jansen, C. A. M., Helmerhorst, F. M., Cohlen, B. J., et al. (2011) · Human Reproduction · doi:10.1093/humrep/der322 · Cited by 190
Valentin, L., Ameye, L., Jurkovic, D., Metzger, U., Lécuru, F., Van Huffel, S., & Timmerman, D. (2006) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.2707 · Cited by 182
Valentin, L. (1999) · Ultrasound in Obstetrics & Gynecology · doi:10.1046/j.1469-0705.1999.14050338.x · Cited by 179
Sherman, M. E., Mink, P. J., Curtis, R., Cote, T. R., Brooks, S., Hartge, P., & Devesa, S. (2004) · Cancer · doi:10.1002/cncr.20080 · Cited by 179
Laparoscopic management of borderline ovarian tumors: results of a French multicenter study
Fauvet, R., Boccara, J., Dufournet, C., Poncelet, C., & Daraï, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi083 · Cited by 175
Serous borderline tumors of the ovary with noninvasive peritoneal implants
Gershenson, D. M., Silva, E. G., Tortolero-Luna, G., Levenback, C., Morris, M., & Tornos, C. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10<2157::aid-cncr14>3.0.co;2-d · Cited by 173
The diagnostic value of PET/CT for primary ovarian cancer—A prospective study
RISUM, S., HOGDALL, C., LOFT, A., BERTHELSEN, A., HOGDALL, E., NEDERGAARD, L., LUNDVALL, L., & ENGELHOLM, S. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.11.022 · Cited by 171
Surface Epithelial Tumors of the Ovary
Seidman, J. D., Cho, K. R., Ronnett, B. M., & Kurman, R. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0489-8_14 · Cited by 168
The Behavior of Serous Tumors of Low Malignant Potential
Kurman, R. J., & Trimble, C. L. (1993) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199304000-00006 · Cited by 161
Valentin, L. (1999) · Ultrasound in Obstetrics & Gynecology · doi:10.1046/j.1469-0705.1999.14040273.x · Cited by 161
Risk Factors for Epithelial Borderline Ovarian Tumors: Results of a Swedish Case–Control Study
Riman, T., Dickman, P. W., Nilsson, S., Correia, N., Nordlinder, H., Magnusson, C. M., & Persson, I. R. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6451 · Cited by 160
Seidman, J. D., Soslow, R. A., VANG, R. S., Berman, J. J., Stoler, M. H., Sherman, M. E., Oliva, E., Kajdacsy‐Balla, A., Berman, D. M., & Copeland, L. J. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.03.004 · Cited by 157
Crispens, M. A., Bodurka, D., Deavers, M. T., Lu, K., Silva, E. G., & Gershenson, D. M. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01649-0 · Cited by 153
Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: a review
Fischerová, D. (2011) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.10054 · Cited by 151
Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Shih, I.-M., & Kurman, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0755 · Cited by 142 · cited 1×
“Type II tumors (so-called highgrade tumors) rapidly become progredient without known preinvasive lesions [29, 30].”
Prognostic factors for patients with advanced stage serous borderline tumours of the ovary
Morice, P., Camatte, S., Rey, A., Atallah, D. M., Lhommé, C., Pautier, P., Pomel, C., Coté, J.-F., Haie‐Méder, C., Morice, P., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg173 · Cited by 134
Gorp, T. V., Veldman, J., CALSTER, B. V., Cadron, I., Leunen, K., Amant, F. C., Timmerman, D., & Vergote, I. B. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.003 · Cited by 128
Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary
Uzan, C., Kane, A., Rey, A., Gouy, S., Morice, P., & Morice, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp267 · Cited by 115
Epithelial ovarian cancer: testing the 'androgens hypothesis'
Olsen, C. M., Green, A. C., Nagle, C. M., Jordan, S. J., Whiteman, D. C., Bain, C., Webb, P. M., & on behalf of the Australian Cancer Study Group (Ovarian Cancer) and the Australian Ovarian Cancer Study Group (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0075 · Cited by 113
Are women ready for the HPV vaccine?
Slomovitz, B. M., Sun, C. C., Frumovitz, M., Soliman, P. T., Schmeler, K. M., Pearson, H. C., Berenson, A. B., Ramirez, P. T., Lu, K. H., & Bodurka, D. C. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.02.003 · Cited by 107
McKenney, J. K., Balzer, B. L., & Longacre, T. A. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213299.11649.fa · Cited by 105
HOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer
Fiegl, H., Windbichler, G. H., Mueller‐Holzner, E., Goebel, G., Lechner, M., Jacobs, I. J., & Widschwendter, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23563 · Cited by 104
Camatte, S., Morice, P., Pautier, P., Atallah, D. M., Duvillard, P., & Castaigne, D. (2002) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1016/s1470-0328(02)01359-9 · Cited by 102
Valentin, L., Ameye, L., Savelli, L., Fruscio, R., Leone, F. P., Czekierdowski, A., Lissoni, A., Fischerová, D., Guerriero, S., Holsbeke, C. V., et al. (2011) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.9030 · Cited by 90
External Validation of Diagnostic Models to Estimate the Risk of Malignancy in Adnexal Masses
Van Holsbeke, C., Van Calster, B., Bourne, T., Ajossa, S., Testa, A. C., Guerriero, S., Fruscio, R., Lissoni, A. A., Czekierdowski, A., Savelli, L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0879 · Cited by 87
Clinical management of borderline ovarian tumors
Trillsch, F., Mahner, S., Ruetzel, J. D., Harter, P., Ewald-Riegler, N., Jaenicke, F., & du Bois, A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.90 · Cited by 86
Gotlieb, W. H., Chetrit, A., Menczer, J., Hirsh‐Yechezkel, G., Lubin, F., Friedman, E., Modan, B., & Ben‐Baruch, G. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.02.022 · Cited by 73
Kane, A., Uzan, C., Rey, A., Gouy, S., Camatte, S., Pautier, P., Lhommé, C., Haie-Meder, C., Duvillard, P., & Morice, P. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0263 · Cited by 71
Yazbek, J., Raju, K. S., Ben‐Nagi, J., Holland, T., Hillaby, K., & Jurkovic, D. (2007) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.4002 · Cited by 70
Kumle, M. H., Weiderpass, E., Braaten, T., Adami, H., & Lund, E. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601715 · Cited by 67
Testa, A. C., Ludovisi, M., Mascilini, F., Legge, A. D., Malaggese, M., Fagotti, A., Fanfani, F., Salerno, M. G., Ercoli, A., Scambia, G., et al. (2011) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.10100 · Cited by 62
Ovarian Metastases of Pancreaticobiliary Tract Adenocarcinomas
Meriden, Z., Yemelyanova, A. V., Vang, R., & Ronnett, B. M. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31820508d0 · Cited by 60
The management of borderline epithelial tumors of the ovary
Burger, C. W., Prinssen, H. M., Baak, J. P. A., Wagenaar, N., & Kenemans, P. (2000) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2000.010003181.x · Cited by 59
Testa, A. C., Timmerman, D., Belle, V. V., Fruscella, E., Holsbeke, C. V., Savelli, L., Ferrazzi, E. M., Leone, F. P. G., Marret, H., Tranquart, F., et al. (2009) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.7464 · Cited by 59
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study
Bjørge, T., Lie, A. K., Hovig, E. J., Gislefoss, R. E., Hansen, S., Jellum, E., Langseth, H., Nustad, K., Tropé, C. G., & Dørum, A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602199 · Cited by 57
Valentin, L. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.06.001 · Cited by 52
Huusom, L. D., Frederiksen, K., Høgdall, E. V. S., Glud, E., Christensen, L. H., Høgdall, C. K., Blaakær, J., & Kjær, S. K. (2006) · Cancer Causes & Control · doi:10.1007/s10552-006-0022-x · Cited by 51
Zapardiel, I., Rosenberg, P., Peiretti, M., Zanagnolo, V. L., Sanguineti, F., Aletti, G. D., Landoni, F., Bocciolone, L., Colombo, N., & Maggioni, A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.07.034 · Cited by 50
Franchi, D., Boveri, S., Fruscio, R., Fischerová, D., Guerriero, S., Moruzzi, M. C., Colombo, N., Timmerman, D., Valentin, L., & Testa, A. C. (2012) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.12276 · Cited by 38
LEE, E.-J., Deavers, M. T., Hughes, J. I., Lee, J. H., & Kavanagh, J. J. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00206.x · Cited by 26
Meyer, J. S., Gersell, D. J., & Yim, S. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6184 · Cited by 11
Micropapillary Serous Carcinoma: The Solution to the Ovarian Borderline Tumor Conundrum
Seidman, J. D., & Varallo, M. R. (2007) · Pathology Case Reviews · doi:10.1097/pcr.0b013e318125674e · Cited by 4
Cited by
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Metadata
- Authors
- Fischerova, D., Zikan, M., Dundr, P., & Cibula, D.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-28
- Volume
- 17
- Issue
- 12
- Pages
- 1515-1533
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2153780770
- Cited by
- 279
- References
- 77
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.